NCT05108051View on ClinicalTrials.gov

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Drug-drug Interaction
Interventions
DRUG

ZSP1273

ZSP1273 tablets 600mg administered orally once daily

DRUG

Oseltamivir

Oseltamivir 75mg administered orally twice daily

Trial Locations (1)

510000

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT05108051 - Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir | Biotech Hunter | Biotech Hunter